R. Hindes - Concepedia

Author

R. Hindes

Bristol-Myers Squibb (United States)

Also Known As

N Spiegelmacher, R G Hindes, R Hindes, R. Hindes, R.G. Hindes, Robert G Hindes, Robert G. Hindes, Robert Hindes

Publications

5.3K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Gilead Sciences (United States)Bristol-Myers Squibb (Germany)Hôpital Cochin Digestive & Liver Disease Specialists

About

R. Hindes is an author at Bristol-Myers Squibb (United States) specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	2K
2	Health Sciences	1	1	48
3	Natural Sciences	1	1	36
4	Public Health	1	1	42
5	Emergency Medicine	1	1	42

R. Hindes

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection Mark Sulkowski, David Gardiner, M. Rodríguez‐Torres, New England Journal of Medicine	2014	1.2K
Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡ Ting‐Tsung Chang, Yun‐Fan Liaw, Shun-Sheng Wu, Hepatology	2010	977
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward Gane, Catherine Stedman, Robert H. Hyland, New England Journal of Medicine	2013	754
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B Morris Sherman, Cihan Yurdaydın, Jose D. Sollano, Gastroenterology HepatologyViral HepatitisHepatitis BHepatitisAntiviral Therapy	2006	413
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Eric Lawitz, Jay Lalezari, Tarek Hassanein, The Lancet Infectious Diseases HepatologyHepatitis CGenotypes 1Viral HepatitisAntiviral Drug Development	2013	328
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Kris V. Kowdley, Eric Lawitz, Israel Crespo, The Lancet Hepatitis CMulticentre Phase 2Viral HepatitisAntiviral Drug DevelopmentAntiviral Therapy	2013	296
A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients Ting‐Tsung Chang, Robert G. Gish, Stephanos J. Hadziyannis, Gastroenterology HepatologyViral HepatitisHepatitis BHepatitisAntiviral Therapy	2005	248
Entecavir therapy for lamivudine‐refractory chronic hepatitis B Morris Sherman, Cihan Yurdaydın, Halis Şimşek, Hepatology	2008	168
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial Stanislas Pol, Reem Ghalib, Vinod K. Rustgi, The Lancet Infectious Diseases HepatologyHepatitis CViral HepatitisAntiviral TherapyHepatitis	2012	147
Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C Robert J. Fontana, Eric Hughes, Marc Bifano, American Journal of Transplantation TransplantationHepatologyHepatitis CViral HepatitisDaclatasvir Combination Therapy	2013	141

Page 1